Gilead Sciences, Inc.





Market Closed - Nasdaq 04:00:00 2023-11-29 pm EST Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
75.23 USD +0.97% -0.62% -12.37%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Amazon: 'Black Friday' and 're:Invent' support the stock CF
Transcript : Gilead Sciences, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:00 AM CI
Novartis' Kymriah, Other CAR-T Cancer Therapies Under US Investigation Over Alleged Safety Issues MT
US FDA investigating safety risk of CAR-T cancer therapies RE
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup DJ
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells DJ
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies MT
Transcript : Gilead Sciences, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-28-2023 01:20 PM CI
US FDA investigating safety risk of CAR-T therapies RE
HOOKIPA Pharma's HIV Vaccine Candidate HB-500 Receives FDA Clearance for Investigational New-Drug Application MT
China Excludes Fosun Kite's Yescarta from Medical Insurance Program MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Sector Update: Health Care MT
Arcellx Shares Rise Premarket on Expanded Gilead Collaboration DJ
Arcellx Expands Partnership With Gilead Unit Kite MT
Gilead Invests Further in Arcellx, Extends Collaboration DJ
Transcript : Gilead Sciences, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-15-2023 09:00 AM CI
Arcellx, Inc. announced that it expects to receive $199.999991 million in funding from Gilead Sciences, Inc. CI
RBC Trims Price Target on Gilead Sciences to $77 From $78, Keeps Sector Perform Rating MT
UBS Adjusts Price Target on Gilead Sciences to $81 From $85, Maintains Neutral Rating MT
Wall Street: a surge in interest rates breaks the bullish rally CF
Deutsche Bank Initiates Coverage on Gilead Sciences With Hold Rating, $75 Price Target MT
Health Care Slips as Biotechs Struggle -- Health Care Roundup DJ
ANALYST RECOMMENDATIONS : AMD, Chevron, Ebay, Quanta Services, UPS...
Chart Gilead Sciences, Inc.
More charts
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
1st Jan change Capi. (M$)
-12.37% 92 843 M $
+61.78% 532 B $
+46.99% 452 B $
-13.89% 365 B $
-8.85% 254 B $
-14.30% 244 B $
-18.62% 216 B $
+1.50% 200 B $
-10.57% 195 B $
-41.30% 168 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
  4. News Gilead Sciences, Inc.
  5. Piper Sandler Lowers Gilead Sciences' Price Target to $100 From $105, Overweight Rating Kept
-40% off Black Friday : Our subscriptions help you unlock the best investment opportunities.
Enjoy this offer